| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9954791 | Biomedicine & Pharmacotherapy | 2018 | 10 Pages |
Abstract
Here, we discuss targeting XIAP, a strategy to restore TRAIL sensitivity in leukemia to acquire more insights into the mechanisms of TRAIL resistance. The concluding remarks may lead to identify putative ways to resensitize tumors.
Keywords
BH3 interacting-domain death agonistXIAPMcl-1Bcl-2cellular FLICE-inhibitory proteinIAPcFLIPDCRDISCIκBαFADDMyeloid cell leukemia-1NFκBBaxApoptosisNK cellNatural killer cellnuclear factor kappa BTRAILB-cell lymphoma 2leukemiaTNF-related apoptosis-inducing ligandDrug resistanceinhibitor of apoptosis proteinsinhibitor of kappa BBcl-2-associated X proteinX-linked Inhibitor of Apoptosis ProteinFas-associated protein with death domainBIDdeath-inducing signaling complexDecoy receptordeath receptor
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Raedeh Saraei, Masoud Soleimani, Ali Akbar Movassaghpour Akbari, Majid Farshdousti Hagh, Ali Hassanzadeh, Saeed Solali,